Tru-pe
Tru-pe has been studied in 1 paper since 2026: none in people yet, 1 in cells; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Feb 21, 2026: “TRU-PE: A Universal, Trackable Prime Editor Toolkit for Robust Single- and Multi-Locus Genome Engineering”.
1 paper studies it1 findingUpdated
At a glance
The findings reach cells, none yet in people. 1 lab in 1 country.
Cells: a single group. Worms or flies, mice and humans: nothing yet.
- 1 lab in 1 country
- Cells1
What did studies of tru-pe find?
1Studies of tru-pe measured one outcome, GATA2 deficiency disease modeling.
GATA2 deficiency disease modeling
upin human cells1
1 study
GATA2 deficiency disease modeling
upin human cells1
Tru-pe improves GATA2 deficiency disease modeling in human cells (human iPSC platform for GATA2 deficiency).
“accurately recapitulates genotype-specific hematopoietic defects”
Cellshuman iPSC platform for GATA2 deficiencyhematopoietic
bioRxivPreprint
Latest
1 paper in 12 monthsbioRxiv
TRU-PE: A Universal, Trackable Prime Editor Toolkit for Robust Single- and Multi-Locus Genome Engineering
Preprint: experiments in human cellsInterventions